TITLE

Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease

AUTHOR(S)
André, P.; Thébaud, B.; Odièvre, M. H.; Razafimahefa, H.; Zupan, V.; Dehan, M.; Lacaze-Masmonteil, T.
PUB. DATE
October 2000
SOURCE
Intensive Care Medicine;Oct2000, Vol. 26 Issue 10, p1496
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To evaluate the benefits and the medium-term side effects of methylprednisolone in very preterm infants at risk of chronic lung disease. Study design: Forty-five consecutive preterm infants (<30 weeks' gestation) at risk of chronic lung disease were treated at a mean postnatal age of 16 days with a tapering course of methylprednisolone. The outcome of treatment was assessed by comparison with 45 consecutive historical cases of infants treated with dexamethasone; the infants did not differ in baseline characteristics. Results: There were no differences between groups in the rate of survivors without chronic lung disease. Infants treated with methylprednisolone had a higher rate of body weight gain during the treatment period (median 120 g, range 0 to 190, vs. 70 g, range –110 to 210, P=0.01) and between birth and the age of 40 weeks (median 1660 g, range 1170–2520, vs. 1580 g, range 1040 to 2120, P=0.02). The incidence of both glucose intolerance requiring insulin (0% vs. 18%, P=0.006) and cystic periventricular leukomalacia (2% vs. 18%, P=0.03) was lower among methylprednisolone-treated infants. Conclusion: Our observations confirm methylprednisolone to be as effective as dexamethasone and to have fewer side effects. A randomized control trial is needed to further study the efficacy and safety of methylprednisolone in very premature infants at risk of chronic lung disease.
ACCESSION #
15729171

 

Related Articles

  • Influence of and Optimal Insulin Therapy for a Low-Glycemic Index Meal in Children With Type 1 Diabetes Receiving Intensive Insulin Therapy. Ryan, Rochelle L.; King, Bruce R.; Anderson, Donald G.; Attia, John R.; Collins, Clare E.; Smart, Carmel E. // Diabetes Care;Aug2008, Vol. 31 Issue 8, p1485 

    OBJECTIVE--The purpose of this study was to quantify the effects of glycemic index on postprandial glucose excursion (PPGE) in children with type 1 diabetes receiving multiple daily injections and to determine optimal insulin therapy for a low-glycemic index meal. RESEARCH DESIGN AND...

  • Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Weinzimer, Stuart A.; Steil, Garry M.; Swan, Karena L.; Dziura, Jim; Kurtz, Natalie; Tamborlane, William V. // Diabetes Care;May2008, Vol. 31 Issue 5, p934 

    OBJECTIVE -- The most promising β-cell replacement therapy for children with type 1 diabetes is a closed-loop artificial pancreas incorporating continuous glucose sensors and insulin pumps. The Medtronic MiniMed external physiological insulin delivery (ePID) system combines an external pump...

  • Insulin Sensitivity in Prepubertal Caucasian Normal Weight Children. Masuccio, Fabio G.; Lattanzio, Franca M.; Matera, Sabino; Giannini, Cosimo; Chiarelli, Francesco; Mohn, Angelika // Journal of Pediatric Endocrinology & Metabolism;Aug2009, Vol. 22 Issue 8, p695 

    The article examines the reliability of reference values provided by the homeostasis model assessment of insulin resistance (HOMA-IR) and the whole body insulin sensitivity index (WBISI) in determining whether or not a prepubertal Caucasian child is insulin-resistant. It compares the two tests...

  • Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus. Szypowska, Agnieszka; Skórka, Agata; Pańkowska, Ewa // Pediatric Endocrinology, Diabetes & Metabolism;2008, Vol. 14 Issue 2, p117 

    Lipoatrophy as a cutaneous complication of insulin therapy has been practically forgotten since the introduction of recombinant human insulin. Here we present two cases of marked lipoatrophy associated with rapid-acting insulin analogues (aspart and lispro) administered with continuous...

  • Preteens, teens doubled use of diabetes drugs. Kalvaitis, Katie // Endocrine Today;12/10/2008, Vol. 6 Issue 22, p1 

    The article deals with a study that examined trends and quarterly prevalence of chronic medication use in children. Results showed that the use of antidiabetes medications increased by 16% among girls aged 10-14 years between 2002 and 2005. Emily R. Cox of Express Scripts Inc. said these...

  • Insulin Sensitivity in the Offspring of Woman With Type 1 and Type 2 Diabetes. Hunter, Wendy A.; Hofman, Paul L.; Harris, Mark; Regan, Fiona; Cutfield, Wayne S.; Cundy, Tim; Rabone, Diana; Robinson, Elizabeth // Diabetes Care;May2004, Vol. 27 Issue 5, p1148 

    OBJECTIVE — To determine if insulin sensitivity is altered in prepubertal offspring exposed to a diabetic intrauterine environment. RESEARCH DESIGN AND METHODS — Fifteen control children, 17 offspring of type 1 diabetic women, and l0 offspring of type 2 diabetic women, aged between...

  • Lipoatrophy with insulin analogues in type I diabetes. Babiker, Amir; Datta, Vipan // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2011, Vol. 96 Issue 1, p101 

    Lipoatrophy is a rare complication of treatment with insulin analogues. It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). To our knowledge, this is one of the first reports of lipoatrophy with Aspart, biphasic...

  • Outpatient Management vs In-Hospital Management of Children with New-Onset Diabetes. Chase, H. Peter; Crews, Kent R.; Garg, Satish; Crews, Michael J.; Cruickshanks, Karen J.; Klingensmith, Georgeanna; Gay, Elizabeth; Hamman, Richard F. // Clinical Pediatrics;Aug1992, Vol. 31 Issue 8, p450 

    The long-term results of outpatient management of subjects with newly diagnosed insulin-dependent diabetes mellitus (IDDM) are unknown. The longest follow-up described to date is for only one year, a time when most children with IDDM still make endogenous insulin. In this study, 41 young...

  • Elevated Plasma Levels of Apelin in Children with Type 1 Diabetes Mellitus. Meral, Cihan; Tascilar, Emre; Karademir, Ferhan; Tanju, Ilhan Asya; Cekmez, Ferhat; Ipcioglu, Osman Metin; Ercin, Cemal Nuri; Gocmen, Ismail; Dogru, Teoman // Journal of Pediatric Endocrinology & Metabolism;May2010, Vol. 23 Issue 5, p497 

    The article offers information on a study which assessed apelin concentrations in diabetic children, and examined the relationship of apelin and adinopectin, body mass index (BMI), lipids and insulin sensitivity. It offers a brief information on apelin, a novel adipocytokine. A discussion on the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics